Equasens (STU:PHF) 5-Year Yield-on-Cost %: 5.94 (As of Jul. 26, 2026) — 200% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PHF Equasens STU:PHF
79 GF Score
Price €33.95
GF Value €56.32
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Equasens 5-Year Yield-on-Cost %?

Equasens STU:PHF +2.26% 79 5-Year Yield-on-Cost % is 5.94 as of Jul. 26, 2026, which is 200% above its 10-year median of 1.98. GuruFocus rates STU:PHF with a GF Score™ of 79/100 and a GF Value™ of €56.32 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 277 Healthcare Providers & Services companies, Equasens ranks better than 77.62% on this metric.

Equasens's yield on cost for the quarter that ended in Dec. 2025 was 5.94.


The historical rank and industry rank for Equasens's 5-Year Yield-on-Cost % or its related term are showing as below:

STU:PHF' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.1   Med: 1.98   Max: 5.94
Current: 5.94


During the past 13 years, Equasens's highest Yield on Cost was 5.94. The lowest was 1.10. And the median was 1.98.


STU:PHF's 5-Year Yield-on-Cost % is ranked better than
77.62% of 277 companies
in the Healthcare Providers & Services industry
Industry Median: 2.93 vs STU:PHF: 5.94

Equasens  (STU:PHF) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Equasens 5-Year Yield-on-Cost % Related Terms


STU:PHF vs VEEV, BTSG, TEM: 5-Year Yield-on-Cost % Comparison

For the Health Information Services subindustry, Equasens's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Equasens 5-Year Yield-on-Cost % vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Equasens's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Equasens's 5-Year Yield-on-Cost % falls into.


STU:PHF
79GF Score
Equasens STU:PHF
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Equasens 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Equasens is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 5.94 mean?
Equasens (STU:PHF) has a 5-Year Yield-on-Cost % of 5.94 as of Jul. 26, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Equasens and its competitors. This is 200% above median its historical median of 1.98. Over the past decade, Equasens' 5-Year Yield-on-Cost % has ranged from 1.10 to 5.94. According to the industry distribution chart, Equasens ranks #62 out of 277 companies in the Healthcare Providers & Services industry, placing it in the top 22.4%.
Is Equasens' 5-Year Yield-on-Cost % too high?
Equasens' current 5-Year Yield-on-Cost % of 5.94 is 200% above median its 10-year median of 1.98. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 5.94. The Healthcare Providers & Services industry median 5-Year Yield-on-Cost % is 2.93. Equasens' value of 5.94 is 102.7% above this industry median. Based on the distribution chart, Equasens ranks #62 out of 277 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Equasens has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Equasens' 5-Year Yield-on-Cost % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Equasens ranks #62 out of 277 companies for 5-Year Yield-on-Cost %. This places Equasens in the top 22% of its industry — outperforming the majority of peers. The industry median 5-Year Yield-on-Cost % is 2.93. Equasens' value of 5.94 is 102.7% above this benchmark. Historically, Equasens' own 5-Year Yield-on-Cost % has ranged from 1.10 to 5.94 over the past decade. While the company's 10-year median is 1.98 vs. the industry median of 2.93, Equasens has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Healthcare Providers & Services company?
The median 5-Year Yield-on-Cost % among Healthcare Providers & Services companies is 2.93, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Equasens's current 5-Year Yield-on-Cost % of 5.94 is 102.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Equasens and its competitors. For the Healthcare Providers & Services industry, the median 5-Year Yield-on-Cost % is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Equasens's current 5-Year Yield-on-Cost % is 5.94, which is 200% above median its own 10-year median of 1.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Equasens stock overvalued right now?
Based on GuruFocus' analysis, Equasens (STU:PHF) is currently considered Significantly Undervalued. The stock's GF Value™ is €56.32, compared to a current price of €33.95 — trading 39.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 5.94, which is 200% above median its 10-year median of 1.98 and 102.7% above the Healthcare Providers & Services industry median of 2.93. Equasens' overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Equasens (STU:PHF), the current 5-Year Yield-on-Cost % is 5.94 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Equasens (STU:PHF) Overvalued in 2026?

Based on GuruFocus' analysis, Equasens stock appears to be undervalued. The current stock price of €33.95 is trading 39.7% below its estimated GF Value™ of €56.32. GuruFocus considers Equasens to be Significantly Undervalued.

Key valuation signals for STU:PHF:

  • 5-Year Yield-on-Cost %: 5.94 (200% above median its 10-year median of 1.98)
  • GF Value™: €56.32 vs. price of €33.95 (39.7% below fair value)
  • GF Score™: 79/100 with 3 warning signs
  • Industry Position: 102.7% above the Healthcare Providers & Services median (#62 of 277)

No single metric tells the full story. See the STU:PHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Equasens Business Description

Other Exchanges EQSp:UK0R9T:UKEQS:France
Address 5 Allee de Saint-Cloud, Technopole de Nancy Brabois, Villers-les-Nancy, FRA, 54600
Equasens is engaged in the European healthcare sector, providing software solutions to all healthcare professionals (pharmacists, primary care practitioners, hospitals, Hospital-at-Home structures, retirement homes, health centers) and patients in both primary and secondary care sectors. The various activities that the company is involved in include: pharmacy software publishing and integration, publishing of IT solutions for health and medical/social establishments, and development of solutions and infrastructures for e-Health. With operations in France (its key revenue-generating market), Italy, Belgium, Germany, Ireland, and the United Kingdom, it is developing the healthcare platform and an ecosystem in France and Europe, benefiting people by making its technology services available.
79GF Score

Get the complete analysis for STU:PHF

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€33.95
Price
€56.32
GF Value